Stefan Sperl
Chief Operating Officer at KIORA PHARMACEUTICALS, INC.
Profile
Stefan Sperl is the founder of Panoptes Pharma GmbH, which was founded in 2013.
He held the title of Chief Operating Officer at the company.
Currently, he is the Executive Vice President-CMC & Operations at Kiora Pharmaceuticals, Inc. He previously worked as a Project Manager at Nabriva Therapeutics GmbH.
Dr. Sperl obtained a doctorate degree from the Max Planck Institute of Biochemistry.
Stefan Sperl active positions
| Companies | Position | Start |
|---|---|---|
| KIORA PHARMACEUTICALS, INC. | Chief Operating Officer | - |
Former positions of Stefan Sperl
| Companies | Position | End |
|---|---|---|
Nabriva Therapeutics GmbH
 Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Corporate Officer/Principal | - |
Panoptes Pharma GmbH
 Panoptes Pharma GmbH BiotechnologyHealth Technology Panoptes Pharma GmbH develops molecule drugs to treat eye diseases. The firm focuses on a new treatment for autoimmune uveitis, a disease which is one of the major causes of blindness. The company was founded by Franz Obermayr and Stefan Sperl in July 2013 and is headquartered in Wien, Austria. | Founder | - |
Training of Stefan Sperl
| Max Planck Institute of Biochemistry | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| KIORA PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Health Technology |
Panoptes Pharma GmbH
Panoptes Pharma GmbH BiotechnologyHealth Technology Panoptes Pharma GmbH develops molecule drugs to treat eye diseases. The firm focuses on a new treatment for autoimmune uveitis, a disease which is one of the major causes of blindness. The company was founded by Franz Obermayr and Stefan Sperl in July 2013 and is headquartered in Wien, Austria. | Health Technology |
- Stock Market
- Insiders
- Stefan Sperl
